# SB-332235

**Cat. No.:** HY-16981  
**CAS No.:** 276702-15-9  
**Molecular Formula:** $C_{13}H_{10}Cl_{3}N_{3}O_{4}S$  
**Molecular Weight:** 410.66  
**Target:** CXCR  
**Pathway:** GPCR/G Protein; Immunology/Inflammation  
**Storage:** Please store the product under the recommended conditions in the Certificate of Analysis.

---

## BIOLOGICAL ACTIVITY

**Description**  
SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist, with an IC$_{50}$ of 7.7 nM. SB-332235 displays 285-fold selectivity for CXCR2 over CXCR1. SB-332235 inhibits acute and chronic models of arthritis in the rabbit. SB-332235 inhibits viability of AML cells\(^1\)[2].

**In Vitro**  
SB-332235 (1-100 μM; 48 hours) inhibits viability of AML cell lines\(^2\).  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.  
**Cell Viability Assay\(^2\)**

<table>
<thead>
<tr>
<th>Cell Line:</th>
<th>AML cell</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concentration:</td>
<td>1, 10, 100 μM</td>
</tr>
<tr>
<td>Incubation Time:</td>
<td>48 hours</td>
</tr>
<tr>
<td>Result:</td>
<td>Led to a dose-dependent decrease in proliferation in all cell lines.</td>
</tr>
</tbody>
</table>

**In Vivo**  
SB-332235 (25 mg/kg, p.o., b.i.d.) exhibits significantly reduced numbers of total leukocytes in synovial fluids from IL-8-injected knees\(^1\).  
SB-332235 (10-25 mg/kg; p.o.; twice a day for 14 days) inhibits chronic Ag-induced arthritis\(^1\).  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

<table>
<thead>
<tr>
<th>Animal Model:</th>
<th>Adult female New Zealand White rabbits (chronic OVA-induced model of arthritis)(^1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosage:</td>
<td>10, 25 mg/kg</td>
</tr>
<tr>
<td>Administration:</td>
<td>P.o.; twice a day for 14 days</td>
</tr>
<tr>
<td>Result:</td>
<td>Day-15 synovial fluid leukocyte numbers in OVA-injected knees were significantly reduced in rabbits. The decrease in neutrophils, monocytes, and lymphocytes resulting from treatment with 25 mg/kg of the antagonist was accompanied by a significant reduction in synovial fluid PGE2, LTBA, LTC4, and IL-8 levels.</td>
</tr>
</tbody>
</table>
REFERENCES


Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA